Delving into the Latest Updates on Covigenix VAX-001 with Synapse

Overview

Basic Info

Drug Type

DNA vaccine, Prophylactic vaccine

Synonyms

Covigenix VAX-001-1b

Target-

Mechanism

Immunostimulants

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Entos Pharmaceuticals, Inc.Startup

Active Organization

Entos Pharmaceuticals, Inc.Startup

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

This study is a Phase I/II clinical study in healthy adults designed to assess the safety, tolerability, and immunogenicity of receiving 2 IM injections of Covigenix VAX-001/-1b, 28 days apart. Covigenix VAX-001/-1b is a plasmid DNA vaccine that expresses key antigenic determinants from SARS-CoV-2 and uses Entos Pharmaceuticals' Fusogenix PLV platform.
The phase I part of this study was completed in Canada. The phase II part of the study will be completed in Burkina Faso, Senegal and South Africa.

Start Date07 Apr 2021

Sponsor / Collaborator

Entos Pharmaceuticals, Inc.Startup

[+2]

100 Clinical Results associated with Covigenix VAX-001

Login to view more data

100 Translational Medicine associated with Covigenix VAX-001

Login to view more data

100 Patents (Medical) associated with Covigenix VAX-001

Login to view more data

100 Deals associated with Covigenix VAX-001

Login to view more data